March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim clinical data from its ...

CN Bio, a leading provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix ® Core. Combining the capabilities of ...

Siemens launches new SIRIUS 3RQ4 coupling relay with three versatile variants for a wide range of industrial requirements ...

This strategic collaboration will leverage Lilly's deep expertise in metabolic diseases and Remedium's proprietary subcutaneously administered gene delivery system to develop and commercialize ...

INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a ...

· Research focused on long-acting therapeutics based on Remedium's proprietary Prometheus platform · Multiple targets for the treatment of Obesity and Type 2 Diabetes BOSTON, MASSACHUSETTS / ACCESS ...

Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel ...

Bio-PE is derived from biological sources like sugarcane instead of petroleum. The manufacturing process begins with extracting ethanol from sugarcane, which is then dehydrated to produce ethylene, ...

Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and ...

Mustang Bio Inc (NASDAQ:MBIO) shares are trading sharply higher Monday afternoon. The company earlier saw a positive development as the FDA granted Orphan Drug Designation to its cell therapy ...

Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...